Catalyst Pharmaceuticals, Inc.
(NASDAQ : CPRX)

( )
CPRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. 8.39%47.650.0%$182.73m
HZNPHorizon Therapeutics Plc 3.53%102.045.4%$177.52m
VRXValeant Pharmaceuticals International, Inc. 3.49%25.1914.1%$148.22m
CTLTCatalent, Inc. 2.18%123.502.0%$130.63m
ICLRICON plc 4.76%278.592.8%$113.63m
CPIXCumberland Pharmaceuticals, Inc. -17.58%5.720.6%$81.06m
JAZZJazz Pharmaceuticals Plc 1.88%123.792.1%$79.06m
UTHRUnited Therapeutics Corp. 0.90%190.4113.9%$73.23m
PRGOPerrigo Co. Plc 0.97%37.406.9%$67.14m
BHCBausch Health Cos., Inc. 3.49%25.190.0%$61.53m
ARGXargenx SE 4.86%292.520.0%$59.83m
ENDPEndo International Plc 4.98%5.278.5%$34.16m
PCRXPacira Biosciences, Inc. 4.99%56.809.8%$26.44m
QLGNQualigen Therapeutics, Inc. 7.63%1.270.0%$26.25m
IRWDIronwood Pharmaceuticals, Inc. 2.23%11.449.5%$25.83m

Company Profile

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.